Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

4.02
Delayed Data
As of Jul 29
 -0.06 / -1.47%
Today’s Change
3.12
Today|||52-Week Range
48.99
-59.92%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$154.5M

Company Description

Tetraphase Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of tetracycline antibiotics. Its portfolio includes Eravacycline, TP-271, and TP-6076. These products targets the treatment of urinary tract infections and community-acquired bacterial pneumonia. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Contact Information

Tetraphase Pharmaceuticals, Inc.
480 Arsenal Street
Watertown Massachusetts 02472
P:(617) 715-3600
Investor Relations:
(617) 600-7040

Employees

Shareholders

Other institutional36.70%
Individual stakeholders31.02%
Mutual fund holders29.28%

Top Executives

Guy MacDonaldPresident, CEO & Class II Director
Christopher WattPrincipal Financial & Accounting Officer
Patrick Taylor HornChief Medical Officer
Jacques DumasChief Scientific Officer
Maria D. StahlSenior Vice President & General Counsel